Analysis

Bridgebio Oncology Therapeutics, Inc. (BBOT) Stock Analysis

Bridgebio Oncology Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to BBOT.

websiteBBOT/analysis/BBOT

Bridgebio Oncology Therapeutics, Inc.

Bridgebio Oncology Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to BBOT.

Stock profile

Ticker

BBOT

Asset type

Stock

Market cap

$605.6M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Bridgebio Oncology Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • BBOT primary listing

Latest Bridgebio Oncology Therapeutics, Inc. news

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data...

BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Model...

BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutan...

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meet...

BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with ...

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ducta...

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 cli...

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage

Research sections

Valuation

Review valuation context for Bridgebio Oncology Therapeutics, Inc..

Future growth

Review future growth context for Bridgebio Oncology Therapeutics, Inc..

Past performance

Review past performance context for Bridgebio Oncology Therapeutics, Inc..

Financial health

Review financial health context for Bridgebio Oncology Therapeutics, Inc..

Dividend

Review dividend context for Bridgebio Oncology Therapeutics, Inc..

Management

Review management context for Bridgebio Oncology Therapeutics, Inc..

Ownership

Review ownership context for Bridgebio Oncology Therapeutics, Inc..

Other information

Review other information context for Bridgebio Oncology Therapeutics, Inc..

Community

Review community context for Bridgebio Oncology Therapeutics, Inc..